We have uncovered new cellular mechanisms for adaptive immune responses mediated by glycoconjugate immunization. Following immunization, glycoconjugates undergo enzymatic and oxidative changes resulting in relatively small glycan-peptides being mounted onto MHCII, with the peptide serving as the MHCII anchor and the carbohydrate presented to and recognized by the CD4+T cell (Tcarb). Importantly, the peptide is not recognized by the Tcarb, only the glycan. Presentation of the carbohydrate is the key event required for very robust T cell help in order for the B cell to make very high-titered anti-glycan antibodies. Demystifying the Tcell activation mechanisms of glycoconjugate vaccines was a key step towards designing new-generation vaccines as outlined in this proposal. We learned from our mechanistic studies that the most important feature of an ideal glycoconjugate vaccine is enrichment for these glycan-peptide epitopes. We synthesized a prototype new-generation glycoconjugate vaccine and tested it for immunogenicity and protective capacity in comparison to a traditionally made glycoconjugate vaccine. Our results showed that the new-generation vaccine was 50-100x more immunogenic and protective than the traditional vaccine. In this proposal, we build on our mechanistic studies and develop a translational platform for optimizing carbohydrate-based vaccines to produce a new generation of vaccines applicable to many microbial glycans. There are two Specific Aims: 1) Optimization of the platform construct for glycoconjugate vaccines. In this Specific Aim, we will optimize the carrier peptide, the glycan chain length, and the glycoconjugate construction to establish parameters for a new vaccine platform that can be applied to new vaccines;2) We will translate our basic discoveries and use our vaccine platform to make new vaccines against important pathogens such as Francisella tularensis, Burkholderia mallei and pseudomallei, and Brucella abortus. The approach offers a knowledge-based design that will serve as a platform for a wide variety of glycoconjugate vaccines for diseases where vaccines have not been created and to greatly improve current glycoconjugate vaccines.

Public Health Relevance

Markedly improved glycoconjugate vaccines have great potential to deliver safe and very effective immunity to a host of important pathogens. We will develop a platform for making glycoconjugates ofthe highest immunogenicity through rational design based on a new understanding of the mechanisms controlling immune responses to this class of molecules.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI109764-01
Application #
8654382
Study Section
Special Emphasis Panel (ZAI1-LR-M (J1))
Project Start
Project End
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
$790,737
Indirect Cost
$315,298
Name
Harvard University
Department
Type
DUNS #
047006379
City
Boston
State
MA
Country
United States
Zip Code
02115
Moison, Eileen; Xie, Ran; Zhang, Ge et al. (2017) A Fluorescent Probe Distinguishes between Inhibition of Early and Late Steps of Lipopolysaccharide Biogenesis in Whole Cells. ACS Chem Biol 12:928-932
May, Janine M; Owens, Tristan W; Mandler, Michael D et al. (2017) The Antibiotic Novobiocin Binds and Activates the ATPase That Powers Lipopolysaccharide Transport. J Am Chem Soc 139:17221-17224
Surana, Neeraj K; Kasper, Dennis L (2017) Moving beyond microbiome-wide associations to causal microbe identification. Nature 552:244-247
Matano, Leigh M; Morris, Heidi G; Hesser, Anthony R et al. (2017) Antibiotic That Inhibits the ATPase Activity of an ATP-Binding Cassette Transporter by Binding to a Remote Extracellular Site. J Am Chem Soc 139:10597-10600
Pasman, Lesley; Kasper, Dennis L (2017) Building conventions for unconventional lymphocytes. Immunol Rev 279:52-62
Pang, Ting; Wang, Xindan; Lim, Hoong Chuin et al. (2017) The nucleoid occlusion factor Noc controls DNA replication initiation in Staphylococcus aureus. PLoS Genet 13:e1006908
Hudak, Jason E; Alvarez, David; Skelly, Ashwin et al. (2017) Illuminating vital surface molecules of symbionts in health and disease. Nat Microbiol 2:17099
Qiao, Yuan; Srisuknimit, Veerasak; Rubino, Frederick et al. (2017) Lipid II overproduction allows direct assay of transpeptidase inhibition by ?-lactams. Nat Chem Biol 13:793-798
Chamakura, Karthik R; Sham, Lok-To; Davis, Rebecca M et al. (2017) A viral protein antibiotic inhibits lipid II flippase activity. Nat Microbiol 2:1480-1484
Welsh, Michael A; Taguchi, Atsushi; Schaefer, Kaitlin et al. (2017) Identification of a Functionally Unique Family of Penicillin-Binding Proteins. J Am Chem Soc 139:17727-17730

Showing the most recent 10 out of 29 publications